Andra Ap Fonden Bei Gene, Ltd. Transaction History

Andra Ap Fonden

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$131.8 - $202.24 $92,260 - $141,568	-700 Reduced 2.46%	27,800 $3.75 Million
Q2 2022 Aug 15, 2022	BUY	$121.11 - $216.05 $2.59 Million - $4.62 Million	21,400 Added 301.41%	28,500 $4.61 Million
Q4 2021 Feb 15, 2022	BUY	$248.56 - $389.34 $1.76 Million - $2.76 Million	7,100 New	7,100 $1.92 Million
Q3 2021 Nov 12, 2021	SELL	$249.6 - $403.14 $624,000 - $1.01 Million	-2,500 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$292.75 - $367.01 $2.61 Million - $3.27 Million	-8,900 Reduced 78.07%	2,500 $858,000
Q1 2021 May 17, 2021	SELL	$260.64 - $382.12 $599,472 - $878,876	-2,300 Reduced 16.79%	11,400 $3.97 Million
Q4 2020 Feb 12, 2021	BUY	$221.31 - $316.61 $3.03 Million - $4.34 Million	13,700 New	13,700 $3.54 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Andra Ap Fonden, based on Form 13F filings with the SEC.

Stay updated on Andra Ap Fonden with notifications on news.